Head-to-head · WeighScore
FuturHealth vs GetRelief Rx
The verdict
FuturHealth takes it — 65.6/100 to 58.9/100.
FuturHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FuturHealth | GetRelief Rx |
|---|---|---|
| WeighScore | 65.6/100 | 58.9/100 |
| Grade | C | C |
| Scorecard rank | #215 | #353 |
| Semaglutide | $199/mo (compounded) | $269/mo (9 mg dose, compounded oral) |
| Tirzepatide | Not disclosed | $179/mo (16 mg dose, compounded oral) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Graded #215 · C
Strengths
- LegitScript Certified and HITRUST Certified
- Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
- Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
- Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths
Where it loses points
- Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
- BBB complaints describe recurring charges without medication received — confirm cancellation flow first
- Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
- Pricing not shown until after the qualification questionnaire or portal login
- Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Graded #353 · C
Strengths
- Compounded semaglutide and tirzepatide priced publicly — no login required to see costs
- BBB accredited with an A rating (March 2026)
- Free online assessment with no upfront consultation fee
Where it loses points
- Sublingual drops only — no injectable; this delivery method wasn't studied in the STEP/SURMOUNT trials
- Still sells compounded tirzepatide after the FDA ended compounding enforcement discretion in 2025
- No LegitScript, PCAB, or NABP pharmacy certifications found
- Prescriber credentials listed only as 'licensed clinicians' with no detail on degree type
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.